Protalix Biotherapeutics Inc Total Assets
Protalix Biotherapeutics Inc total assets. Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) holds total assets worth $82.35 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Protalix Biotherapeutics Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Protalix Biotherapeutics Inc (1996–2025)
Total assets of Protalix Biotherapeutics Inc from 1996 to 2025. This chart illustrates how Protalix Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Protalix Biotherapeutics Inc stock quote for real-time trading data and today's change.
Protalix Biotherapeutics Inc - Asset Composition Analysis
Protalix Biotherapeutics Inc Total Assets Breakdown (December 2025)
Protalix Biotherapeutics Inc total assets breakdown as of December 2025. Protalix Biotherapeutics Inc's total assets of $82.35 Million consist of 81.0% current assets and 19.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $14.68 Million | 17.8% |
| Accounts Receivable | $8.84 Million | 10.7% |
| Inventory | $25.73 Million | 31.2% |
| Property, Plant & Equipment | $12.58 Million | 15.3% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Protalix Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Protalix Biotherapeutics Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Protalix Biotherapeutics Inc's current assets represent 81.0% of total assets in 2025, a decrease from 99.9% in 1996.
- Cash Position: Cash and equivalents constituted 17.8% of total assets in 2025, up from 10.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 31.2% of total assets.
Protalix Biotherapeutics Inc Competitors by Total Assets
Key competitors of Protalix Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Protalix Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.51 | 2.34 | 1.12 |
| Quick Ratio | 1.54 | 1.52 | 0.95 |
| Cash Ratio | 0.55 | 0.77 | 0.00 |
| Working Capital | $40.16 Million | $34.46 Million | $9.84 Million |
Protalix Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Protalix Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.37 |
| Latest Market Cap to Assets Ratio | 1.90 |
| Asset Growth Rate (YoY) | 12.2% |
| Total Assets | $82.35 Million |
| Market Capitalization | $156.31 Million USD |
Valuation Analysis
Above Book Valuation: The market values Protalix Biotherapeutics Inc's assets above their book value (1.90x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Protalix Biotherapeutics Inc's assets grew by 12.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual total assets of Protalix Biotherapeutics Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $82.35 Million | +12.16% |
| 2024-12-31 | $73.42 Million | -13.05% |
| 2023-12-31 | $84.43 Million | +51.35% |
| 2022-12-31 | $55.79 Million | -24.27% |
| 2021-12-31 | $73.67 Million | +8.44% |
| 2020-12-31 | $67.93 Million | +49.66% |
| 2019-12-31 | $45.39 Million | -25.75% |
| 2018-12-31 | $61.13 Million | -15.35% |
| 2017-12-31 | $72.21 Million | -12.20% |
| 2016-12-31 | $82.25 Million | -15.43% |
| 2015-12-31 | $97.25 Million | +23.94% |
| 2014-12-31 | $78.47 Million | -30.76% |
| 2013-12-31 | $113.33 Million | +43.96% |
| 2012-12-31 | $78.73 Million | +51.97% |
| 2011-12-31 | $51.80 Million | -19.97% |
| 2010-12-31 | $64.73 Million | -34.40% |
| 2009-12-31 | $98.67 Million | +94.19% |
| 2008-12-31 | $50.81 Million | -25.43% |
| 2007-12-31 | $68.14 Million | +152.47% |
| 2006-12-31 | $26.99 Million | +2633.35% |
| 2005-12-31 | $987.36K | +74.50% |
| 2004-12-31 | $565.84K | -22.94% |
| 2003-12-31 | $734.25K | -16.11% |
| 2002-12-31 | $875.22K | -14.46% |
| 2001-12-31 | $1.02 Million | -46.27% |
| 2000-12-31 | $1.90 Million | -7.01% |
| 1999-12-31 | $2.05 Million | -57.09% |
| 1998-12-31 | $4.77 Million | -36.08% |
| 1997-12-31 | $7.47 Million | +1.73% |
| 1996-12-31 | $7.34 Million | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more